Effusion Cytology
Malignant mesothelioma cells with characteristic intracytoplasmic vacuolization and lipids
Diagnostic Cytopathology 2023 August 15 [Link] Satoshi Morito, Hiroshi Yasui, Tomoo Itoh, Shingo Kamoshida, Hiroyuki Ohsaki Abstract In this brief report, we described some uncommon cytomorphological features of malignant mesothelioma (MM) cells in pleural effusions. The tumor cells exhibited abundant cytoplasmic vacuolization, with presence of single or multiple eccentric nuclei in several cells. In the…
Read MoreComparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma
Cytopathology 2023 June 19 [Link] Mohammed S I Mansour, Adela Huseinzade, Tomas Seidal, Kim Hejny, Athar Maty, Fereshteh Taheri-Eilagh, Ulrich Mager, Annika Dejmek, Katalin Dobra, Hans Brunnström Abstract Objective: Traditionally, the diagnosis of pleural mesothelioma is based on histological material. Minimally invasive effusion cytology specimens are an alternative that, like biopsies, require ancillary analyses. Validation…
Read MoreHigh Expression of SMO and GLI1 Genes with Poor Prognosis in Malignant Mesothelioma
Biomed Research International 2023 April 24 [Link] Guan-Ying Ma, Shuai Shi, Yin-Zhou Sang, Ping Wang, Zhi-Gang Zhang Abstract Background: To investigate the value of SMO and GLI1 genes in the hedgehog pathway in malignant mesothelioma specimens. Further study on the expression and prognosis of SMO and GLI1 in malignant mesothelioma tissues and the relationship between…
Read MoreComprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall
Cancer Cytopathology 2023 April 17 [Link] Yili Zhu, Simone Moore, Aihui Wang, Elizabeth George, Grace M Allard, Diane M Libert, Alarice C Lowe Abstract Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma case…
Read MoreEstablishment of an experimental model of canine malignant mesothelioma organoid culture using a three-dimensional culture method
Biomedicine and Pharmacotherapy 2023 June [Link] Yomogi Sato, Mohamed Elbadawy, Kazuhiko Suzuki, Ryouichi Tsunedomi, Hiroaki Nagano, Yusuke Ishihara, Haru Yamamoto, Daigo Azakami, Tsuyoshi Uchide, Rina Nabeta, Ryuji Fukushima, Amira Abugomaa, Masahiro Kaneda, Hideyuki Yamawaki 10, Yuta Shinohara, Tatsuya Usui, Kazuaki Sasaki Abstract Canine malignant mesothelioma (cMM) is a rare and drug-resistant malignant tumor. Due to…
Read MoreThe cytological features of effusions with mesothelioma in situ: A report of 9 cases
Diagnostic Cytopathology 2023 March 21 [Link] Claire W Michael, Carlos C W M Bedrossian, Navid Sadri, Sonja Klebe Abstract Introduction: The diagnosis of mesothelioma in situ (MIS) is now accepted by the WHO as a pre-invasive neoplastic mesothelial proliferation and considered a diagnosis based on histologic evaluation only. Although the definition of MIS includes recurrent…
Read MoreTROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy
Lung Cancer 2023 April [Link] Luca Hegedüs, Özlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schuler, Anja Welt, Silvia Vega-Rubin-de-Celis, Dirk Theegarten, Agnes Bankfalvi, Clemens Aigner, Balazs Hegedüs Abstract Objectives: Malignant pleural mesothelioma (MPM) is an aggressive cancer which at large is not amenable to curative surgery. Despite the recent approval of immune checkpoint…
Read MoreNovel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing
Lung Cancer 2023 April [Link] Hely Ollila-Raj, Astrid Murumägi, Teijo Pellinen, Mariliina Arjama, Eva Sutinen, Kirsi Volmonen, Heidi M Haikala, Olli Kallioniemi, Mikko I Mäyränpää, Ilkka Ilonen Abstract Objectives: Pleural mesothelioma (PM) is an aggressive malignancy with limited treatment options. The first-line therapy has remained unchanged for two decades and consists of pemetrexed in combination…
Read MoreDefining and targeting tumor-associated macrophages in malignant mesothelioma
Proceedings of the National Academy of Sciences of the United States of America 2023 February 28 [Link] Licun Wu, Mikihiro Kohno, Junichi Murakami, Amin Zia, Jonathan Allen, Hana Yun, Meilin Chan, Cristina Baciu, Mingyao Liu, Veronique Serre-Beinier, Michele De Palma, Emanuela Felley-Bosco, Jonathan Yeung, Trevor J Pugh, Marc de Perrot Abstract Defining the ontogeny of…
Read MoreIdentification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics
Cancers 2023 January 19 [Link] Nicolai B Palstrøm, Martin Overgaard, Peter Licht, Hans C Beck Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated, highly aggressive cancer characterized by late-stage diagnosis and poor prognosis. Gold standards for diagnosis are pleural biopsy and cytology of pleural effusion (PE), both of which are limited by low sensitivity and…
Read More